I-MAB

0VY

Company Profile

  • Business description

    I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

  • Contact

    2440 Research Boulevard
    Suite 400
    RockvilleMD20850
    USA

    T: +1 240 745-6330

    https://www.i-mabbiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    32

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,586.7015.300.18%
CAC 407,734.40130.04-1.65%
DAX 4023,629.58369.59-1.54%
Dow JONES (US)41,603.07256.02-0.61%
FTSE 1008,717.9721.29-0.24%
HKSE23,601.2656.950.24%
NASDAQ18,737.21188.53-1.00%
Nikkei 22537,160.47174.600.47%
NZX 50 Index12,596.5065.75-0.52%
S&P 5005,802.8239.19-0.67%
S&P/ASX 2008,360.9012.200.15%
SSE Composite Index3,348.3731.82-0.94%

Market Movers